Vanguard Group’s Acrivon Therapeutics ACRV Stock Holding History

Vanguard Group’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.68M	Buy	698,857 +72,709	+12%	+$158K	﹤0.01%	3614
2025 Q3	$1.13M	Buy	626,148 +32,901	+6%	+$46.2K	﹤0.01%	3753
2025 Q2	$706K	Sell	593,247 -81,543	-12%	-$112K	﹤0.01%	3845
2025 Q1	$1.37M	Buy	674,790 +3,165	+0.5%	+$17K	﹤0.01%	3612
2024 Q4	$4.04M	Buy	671,625 +34,087	+5%	+$248K	﹤0.01%	3351
2024 Q3	$4.46M	Sell	637,538 -107,972	-14%	-$851K	﹤0.01%	3305
2024 Q2	$4.32M	Buy	745,510 +238,325	+47%	+$1.92M	﹤0.01%	3316
2024 Q1	$3.63M	Buy	507,185 +31,208	+7%	+$145K	﹤0.01%	3413
2023 Q4	$2.34M	Buy	475,977 +7,570	+2%	+$40K	﹤0.01%	3549
2023 Q3	$4.48M	Buy	468,407 +65,132	+16%	+$753K	﹤0.01%	3298
2023 Q2	$5.23M	Sell	403,275 -5,940	-1%	-$71.9K	﹤0.01%	3274
2023 Q1	$5.19M	Buy	+409,215	New	+$6.87M	﹤0.01%	3292

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group's ACRV Position: Q4 2025 in Review

Vanguard Group increased its Acrivon Therapeutics (ACRV) stake by 12% in Q4 2025, buying an estimated $158K and bringing the position to 698,857 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #3614.

Vanguard Group first reported a position in ACRV in Q1 2023 and has held it in 12 quarters since. The position peaked at $5.23M in Q2 2023. 48 funds tracked by Wall St. Rank hold ACRV as of Q4 2025.

Vanguard Group held 698,857 shares of Acrivon Therapeutics worth $1.68M as of Q4 2025.
Vanguard Group bought 72,709 Acrivon Therapeutics shares in Q4 2025, an estimated $158K.
Acrivon Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3614 holding.
Vanguard Group first reported a position in Acrivon Therapeutics in Q1 2023 and has held it in 12 quarters since.
Vanguard Group's Acrivon Therapeutics position peaked at $5.23M in Q2 2023.
48 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.